Topics

FDA panel backs Epizyme's tazemetostat to treat epithelioid sarcoma

06:40 EST 19 Dec 2019 | SmartBrief

The FDA's Oncologic Drugs Advisory Committee voted to back the approval of Epizyme's EZH2 inhibitor candidate tazemetostat as -More

Original Article: FDA panel backs Epizyme's tazemetostat to treat epithelioid sarcoma

NEXT ARTICLE

More From BioPortfolio on "FDA panel backs Epizyme's tazemetostat to treat epithelioid sarcoma"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...